Prevention and treatment of synucleinopathic and amyloidogenic disease
First Claim
1. A method of reducing the risk of, lessening the severity of, delaying the outset of or treating a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprisingadministering to a patient having or at risk of the disease an effective regime of a monoclonal antibody that competes with antibody 6H7 deposited as ATCC PTA-6910 for specific binding to alpha synuclein and specifically binds to an epitope within residues 1-10 of human alpha-synuclein, residues being numbered according to SEQ ID NO:
- 1.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson'"'"'s disease.
-
Citations
15 Claims
-
1. A method of reducing the risk of, lessening the severity of, delaying the outset of or treating a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising
administering to a patient having or at risk of the disease an effective regime of a monoclonal antibody that competes with antibody 6H7 deposited as ATCC PTA-6910 for specific binding to alpha synuclein and specifically binds to an epitope within residues 1-10 of human alpha-synuclein, residues being numbered according to SEQ ID NO:
-
11. A method of reducing the risk of, lessening the severity of, delaying the outset of or treating a disease characterized by Lewy bodies or alpha- synuclein aggregation in the brain, the method comprising
administering to a patient having or at risk of the disease an effective regime of a first monoclonal antibody that competes with antibody 6H7 deposited as ATCC PTA-6910 for specific binding to alpha synuclein and specifically binds to an epitope within residues 1-10 of human alpha-synuclein, residues being numbered according to SEQ ID NO: - 1 and administering a second antibody that that specifically binds to an epitope within residues 100-140 of human alpha-synuclein.
- View Dependent Claims (12, 13, 14, 15)
Specification